{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T13:40:33Z","timestamp":1768830033426,"version":"3.49.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.urolonc.2023.11.013","type":"journal-article","created":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T14:17:58Z","timestamp":1705414678000},"page":"110-114","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Estimates of the lead time in screening for bladder cancer"],"prefix":"10.1016","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0697-4853","authenticated-orcid":false,"given":"Jochanan","family":"Benbassat","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2023.11.013_bib0001","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.eururo.2019.10.010","article-title":"Non-visible haematuria for the detection of bladder, upper tract, and kidney cancer: an updated systematic review and meta-analysis","volume":"77","author":"Jubber","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2023.11.013_bib0002","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1002\/cncr.22224","article-title":"Long-term outcome of hematuria home screening for bladder cancer in men","volume":"107","author":"Messing","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2023.11.013_bib0003","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.euo.2019.09.008","article-title":"A systematic review and meta-analysis of delay in radical cystectomy and the effect on survival in bladder cancer patients","volume":"3","author":"Russel","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.urolonc.2023.11.013_bib0004","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1097\/00043764-199009000-00021","article-title":"Bladder cancer screening among primary aluminum production workers in Quebec","volume":"32","author":"Th\u00e9riault","year":"1990","journal-title":"J Occup Med"},{"key":"10.1016\/j.urolonc.2023.11.013_bib0005","doi-asserted-by":"crossref","first-page":"488","DOI":"10.7326\/M15-1496","article-title":"Hematuria as a marker of occult urinary tract cancer: advice for high-value care from the American College of Physicians","volume":"164","author":"Nielsen","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.urolonc.2023.11.013_bib0006","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1097\/JU.0000000000001297","article-title":"Microhematuria: AUA\/SUFU guideline","volume":"204","author":"Barocas","year":"2020","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2023.11.013_bib0007","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s13148-021-01073-x","article-title":"A urine-based DNA methylation assay to facilitate early detection and risk stratification of bladder cancer","volume":"13","author":"Ruan","year":"2021","journal-title":"Clin Epigenet"},{"key":"10.1016\/j.urolonc.2023.11.013_bib0008","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.euo.2021.04.005","article-title":"Clinical utility of cell-free and circulating tumor DNA in kidney and bladder cancer: a critical review of current literature","volume":"4","author":"Green","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.urolonc.2023.11.013_bib0009","doi-asserted-by":"crossref","first-page":"3311","DOI":"10.2217\/fon-2022-0448","article-title":"Bladder cancer diagnosis with a four-miRNA panel in serum","volume":"18","author":"Li","year":"2022","journal-title":"Future Oncol"},{"key":"10.1016\/j.urolonc.2023.11.013_bib0010","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00345-018-2436-y","article-title":"Epidemiology, prevention, screening, diagnosis, and evaluation: update of the ICUD\u2013SIU joint consultation on bladder cancer","volume":"37","author":"Fern\u00e1ndez","year":"2019","journal-title":"World J Urol"},{"key":"10.1016\/j.urolonc.2023.11.013_bib0011","first-page":"993","article-title":"Can hematuria be a predictor as well as a symptom or sign of bladder cancer?","volume":"5","author":"Friedman","year":"1996","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.urolonc.2023.11.013_bib0012","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1186\/1471-2407-14-854","article-title":"Chromosomal alterations in exfoliated urothelial cells from bladder cancer cases and healthy men: a prospective screening study","volume":"14","author":"Bonberg","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.urolonc.2023.11.013_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102643","article-title":"Urinary TERT promoter mutations are detectable up to 10 years prior to clinical diagnosis of bladder cancer: evidence from the Golestan Cohort Study","volume":"53","author":"Hosen","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.urolonc.2023.11.013_bib0014","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1007\/s00330-017-5029-z","article-title":"Baseline and annual repeat rounds of screening: implications for optimal regimens of screening","volume":"28","author":"Henschke","year":"2018","journal-title":"Eur Radiol"},{"key":"10.1016\/j.urolonc.2023.11.013_bib0015","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S0272-2712(18)31034-5","article-title":"Performance characteristics of screening tests","volume":"2","author":"Habbema","year":"1982","journal-title":"Clin Lab Med"},{"key":"10.1016\/j.urolonc.2023.11.013_bib0016","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1136\/bmj.299.6706.1010","article-title":"Dipstick hematuria and bladder cancer in men over 60: results of a community study","volume":"299","author":"Britton","year":"1989","journal-title":"BMJ"},{"key":"10.1016\/j.urolonc.2023.11.013_bib0017","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0090-4295(99)80006-5","article-title":"Comparison of bladder cancer outcome in men undergoing hematuria home screening versus those with standard clinical presentations","volume":"45","author":"Messing","year":"1995","journal-title":"Urology"},{"issue":"1","key":"10.1016\/j.urolonc.2023.11.013_bib0018","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1080\/00365590500368807","article-title":"Screening for bladder tumours in men aged 60\u201370 years with a bladder tumour marker (UBC) and dipstick-detected haematuria using both white-light and fluorescence cystoscopy","volume":"40","author":"Hedelin","year":"2006","journal-title":"Scandinavian journal of urology and nephrology"},{"key":"10.1016\/j.urolonc.2023.11.013_bib0019","unstructured":"Cancer research website. Accessed in July 2023 at https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/bladder-cancer\/incidence"},{"issue":"23","key":"10.1016\/j.urolonc.2023.11.013_bib0020","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.21037\/atm-20-2108","article-title":"An overview of patients with urothelial bladder cancer over the past two decades: a Surveillance, Epidemiology, and End Results (SEER) study","volume":"8","author":"Zang","year":"2020","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.urolonc.2023.11.013_bib0021","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1080\/21681805.2019.1632380","article-title":"Incidence, survival and mortality trends of bladder cancer in Sweden 1997\u20132016","volume":"53","author":"Malmstr\u00f6m","year":"2019","journal-title":"Scand Urol"},{"key":"10.1016\/j.urolonc.2023.11.013_bib0022","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/BF00402063","article-title":"Mass screening for urinary tract cancer with urine cytology","volume":"104","author":"Nemoto","year":"1982","journal-title":"Journal of Cancer Research and Clinical Oncology"},{"issue":"1","key":"10.1016\/j.urolonc.2023.11.013_bib0023","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.juro.2009.02.142","article-title":"Bladder cancer screening in a high risk asymptomatic population using a point of care urine based protein tumor marker","volume":"182","author":"Lotan","year":"2009","journal-title":"The Journal of urology"},{"issue":"1","key":"10.1016\/j.urolonc.2023.11.013_bib0024","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.eururo.2013.02.036","article-title":"Outcomes of a bladder cancer screening program using home hematuria testing and molecular markers","volume":"64","author":"Bangma","year":"2013","journal-title":"European urology"},{"key":"10.1016\/j.urolonc.2023.11.013_bib0025","doi-asserted-by":"crossref","first-page":"426","DOI":"10.2188\/jea.JE20200416","article-title":"Updated trends in cancer in Japan: incidence in 1985\u20132015 and mortality in 1958\u20132018\u2014a sign of a decrease in cancer incidence","volume":"31","author":"Katanoda","year":"2021","journal-title":"J Epidemiol"},{"key":"10.1016\/j.urolonc.2023.11.013_bib0026","unstructured":"Population statistics of Japan by Age and Sex: 1930, 1950. Accessed in July 2023 at https:\/\/www.ipss.go.jp\/p-info\/e\/psj2008\/PSJ2008-02.pdf"},{"key":"10.1016\/j.urolonc.2023.11.013_bib0027","unstructured":"Population statistics of USA by age groups, race, and sex for 1950-2009. Accessed in July 2023 at https:\/\/www.cdc.gov\/nchs\/data\/hus\/2010\/001.pdf"},{"key":"10.1016\/j.urolonc.2023.11.013_bib0028","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.urolonc.2023.11.013_bib0029","unstructured":"Statistics in The Netherlands. Accessed on August 2023 at https:\/\/www.cbs.nl\/en-gb\/visualisations\/dashboard-population\/men-and-women"},{"key":"10.1016\/j.urolonc.2023.11.013_bib0030","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1093\/qjmed\/hch125","article-title":"Asymptomatic isolated microscopic hematuria: long-term follow-up","volume":"97","author":"Chow","year":"2004","journal-title":"QJM"},{"key":"10.1016\/j.urolonc.2023.11.013_bib0031","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.eururo.2017.09.011","article-title":"Monitoring treatment response and metastatic relapse in advanced bladder cancer by liquid biopsy analysis","volume":"73","author":"Birkenkamp-Demtr\u00f6der","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2023.11.013_bib0032","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-017-05623-3","article-title":"Association of plasma and urinary mutant DNA with clinical outcomes in muscle-invasive bladder cancer","volume":"7","author":"Patel","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.urolonc.2023.11.013_bib0033","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/ajim.4700270303","article-title":"Estimation of risk of developing bladder cancer among workers exposed to coal tar pitch volatiles in the primary aluminum industry","volume":"27","author":"Tremblay","year":"1995","journal-title":"Am J Ind Med"},{"key":"10.1016\/j.urolonc.2023.11.013_bib0034","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12890-020-01385-3","article-title":"Duration of lead time in screening for gastric cancer","volume":"21","author":"Benbassat","year":"2021","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.urolonc.2023.11.013_bib0035","doi-asserted-by":"crossref","first-page":"563","DOI":"10.36472\/msd.v8i10.608","article-title":"Duration of lead time in screening for lung cancer","volume":"8","author":"Benbassat","year":"2021","journal-title":"Med Sci Discov"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143923004118?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143923004118?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T03:46:24Z","timestamp":1730864784000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143923004118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S1078143923004118"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2023.11.013","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Estimates of the lead time in screening for bladder cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2023.11.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}